Criteria for dose-finding in two-stage seamless adaptive design

Area of Science:

• Clinical Trial Design
• Pharmaceutical Development
• Biostatistics

Background:

• Two-stage seamless adaptive designs integrate Phase IIb dose-finding and Phase III efficacy studies into a single trial.
• These designs are increasingly utilized in pharmaceutical and clinical development for efficiency.
• Decision-making at the interim stage (end of Stage 1) is critical for selecting doses for Stage 2.

Purpose of the Study:

• To introduce, compare, and evaluate common selection criteria used in two-stage seamless adaptive clinical trials.
• To provide guidance on selecting appropriate criteria for critical decision-making at the interim stage.
• To address practical concerns associated with two-stage seamless adaptive trial designs.

Main Methods:

• Evaluation of four common interim selection criteria: conditional power, precision analysis, predictive probability of success, and probability of being the best dose.
• Utilized simulation studies to compare the performance and characteristics of these criteria.
• Included a numeric example to illustrate the application and interpretation of the criteria.

Main Results:

• The study provides a comparative analysis of the strengths and weaknesses of each evaluated selection criterion.
• Simulation results demonstrate the practical implications of using different criteria in two-stage seamless adaptive designs.
• The numeric example highlights how these criteria can be applied in real-world clinical trial scenarios.

Conclusions:

• The choice of interim selection criteria significantly impacts the success and efficiency of two-stage seamless adaptive trials.
• Understanding and comparing these criteria is essential for robust dose selection and efficacy confirmation in pharmaceutical development.
• The article offers insights into managing concerns and optimizing the application of these advanced clinical trial designs.